Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2013)

21 slides from Pharmacyclics's technical presentation, Jun 17, 2013

  1. Slide 1: Disclosures

    oiclosu res SVEN DE Vos, MD PHD Pharmacyclics (Research Funding, Scientific Advisory Board)

  2. Slide 2: The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, has Preferential Activity in ABC DLBCL

    The Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), has Preferential Activity in the Activated B Cell- like (ABC) Subtype of Relapsed/Refractory (R/R) DLBCL: Interim Phase 2 Results ‘Sven de Vos!, Wyndham H. Wilson?, John Gerecitano®, Andre Goy’, Vaishalee P. Kenkre’, Paul Barré, Kr

  3. Slide 3: Molecular Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL)

    Molecular Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) — aac pisct Probability — ce p1act Probability FoxPL RFA BUNK 039 yetin 02 Pima ‘eM 10 Jawa, BCLS uwoz acmyb GCB DLBCL 274 DLBCL Biopsy Samples

  4. Slide 4: Molecular Subtype Predicts Outcome With R-CHOP

    Molecular Subtype Predicts Outcome With R-CHOP E10 10 5 i z 2 os ge z e é 2 06: = 06 5 ° $ 8 oa & oa & Hiscsowa § Bi ccs pisct 2 02 12 3 Mascon § MB asc ousct Bo) roses P<0.00% & oof 004 . 2a 2 3 4@ 5 . a 2. 3 @ 3 Lanz etal W Engl Med. 2008; 355: 2313, FHA 2013, PCYC1106 de Voret 3

  5. Slide 5: Chronic Active B-Cell Receptor Signaling Activates NF-KB in ABC DLBCL

    Chronic Active B-Cell Receptor Signaling Activates NF-KB in ABC DLBCL NO PRATT] RPK PRK RE SPRPRFPRPRRARARR RRR ROR ey OdbsLEsELELESESESLSLSE A B MyYD88.

  6. Slide 6: Key Pathway Related Mutations Contribute to BTK Signaling in ABC DLBCL

    Key Pathway Related Mutations Contribute to BTK Signaling in ABC DLBCL BCR SPRPRFPRPRRARARR RRR ROR SEdEssSdsESESESESESS A B @ MyYD88

  7. Slide 7: Ibrutinib: A First-in-Class Inhibitor of BTK

  8. Slide 8: Study Hypothesis

    Study Hypothesis e Ibrutinib activity will be restricted to ABC DLBCL ¢ Ibrutinib activity will be dependent on pathogenetic events within the BCR pathway

  9. Slide 9: Study Design

    Study Design e Multi-center (14 sites), open-label, phase II study of ibrutinib in relapsed/refractory de novo DLBCL © Treatment: 560 mg PO daily monotherapy until progression ¢ Primary objective: — Evaluate ibrutinib in relapsed/refractory de novo ABC and GCB DLBCL e Secondary objective: — Evaluate

  10. Slide 10: Patient Eligibility

    Patient Eligibility * Pathologically confirmed de novo DLBCL * Men and women 2 18 years of age * ECOG performance status < 2 * Archival tissue for central review ° Prior treatment: — Progressive disease after autologous transplant (ASCT) — Or considered ineligible for ASCT as outlined in protocol *

  11. Slide 11: Patient Characteristics

    Patient Characteristics Characteristics Total (N = 70) Median age, yrs (range) 64 (28-92) Sex (male), n (%) 50 (71) ECOG PS 2, n(%) 12(17) IPI (HI/High), n (%) 37 (59) Time from diagnosis, median months (range) 19 (5-332) Prior regimens, median (range) 3 (1-7) Prior ASCT, n (%) 16 (23) Refractory di

  12. Slide 12: Patient Characteristics by Gene Expression Profile (GEP) Analysis

    Patient Characteristics by Gene Expression Profile (GEP) Analysis ABC GCB Unclassified — Unknown Characteristics* (N=29) — (N=20) (N= 16) (N=5) Median age, yrs (range) 62 (34-89) 65(28-92) 65 (44-85) 65 (58-78) Sex (male) 69% 70% 81% 60% ECOG PS 2 1% 20% 25% 40% IPI (HI/High) 61% 58% 54% 60% Time fr

  13. Slide 13: Grade 3 or Higher AEs >3% Incidence

    Grade 3 or Higher AEs >3% Incidence (Unrelated and related AEs) Hematologic AEs lymphocyte count decreased Neutropenia Thrombocytopenia Anaemia 0% 5% 10% 15% 20% Non-Hematologic AEs Fatigue Hyponatremia Pneumonia Dehydration Pleural effusion Sepsis 25% [Grade 3 MIB Grades [Grade S

  14. Slide 14: Waterfall Plot of Maximum Decrease in Bi-dimensional Measurements

    Waterfall Plot of Maximum Decrease in Bi-dimensional Measurements 180 ABC (N= 23) I GcB (N= 12) 1304 Unclassifiable (N= 8) I Unknown (N= 3) Change From Baseline SPD, % Only includes pts with post baseline LN measurements -120 + Overall Response Rate — PR 16%, CR 9%, PR¥CR 25% (17/70 patients) * Best

  15. Slide 15: Response in ABC and GCB DLBCL

    Response in ABC and GCB DLBCL 100 4 90 4 80 70 + 60 50 4 P=0.007 41% Response (CR+PR), % ABC DLBCL GCB DLBCL

  16. Slide 16: Time on Study Treatment in ABC and GCB DLBCL

    Time on Study Treatment in ABC and GCB DLBCL Patient still on ibrutinib > T T T T T T 4 6 8 10 12 14 Months on Study

  17. Slide 17: Overall Survival in ABC and GCB DLBCL

    Overall Survival in ABC and GCB DLBCL 1.0. —— ABC Zoe — GcB 4 3 0.6. 3 = 3 04. a P=0.050* 2 02 Number at risk oo} 2 2 16 u 3 o ° 2 0 5 4 3 3 1 T T T T T T T 1 Cy) 3 6 9 wz 1508 Overall Survival, months * Median ABC OS 9.76 (95% Cl: 3.88, 11.63) * Median GCB Os 3.35 (1.22, 7.13) + Based on Wilcoxon T

  18. Slide 18: Analysis of Response Rate Within Mutation Subgroups

    Analysis of Response Rate Within Mutation Subgroups e Mutations in tumor samples analyzed by PCR amplification and Sanger DNA sequencing e ABC DLBCL tumors were analyzed for mutations in CD79B, MYD88 and CARD11 e Includes 29 ABC DLBCL cases in present study (PCYC-1106) and 10 ABC DLBCL cases from a

  19. Slide 19: Mutations in the B-Cell Receptor Signaling Pathway Influence Sensitivity to Ibrutinib

    Mutations in the B-Cell Receptor Signaling Pathway Influence Sensitivity to Ibrutinib BCR Y\ i.072 oO RPPR TY PPR) RRRRROS

  20. Slide 20: Conclusions

    Conclusions * Ibrutinib, a potent covalent inhibitor of BTK, induced a high single-agent response rate in relapsed/refractory ABC DLBCL ¢ Ibrutinib had marginal activity in GCB DLBCL, supporting the use of the ABC DLBCL molecular subtype as a biomarker for activity * Ibrutinib was associated with a

  21. Slide 21: Acknowledgements

    Acknowledgements All of the patients and their families who participated in this trial Investigators and clinical research staff from all participating centers = Metabolism Branch, CCR, NCI + Sameer Jhavar * Art Shafer Pharmacyclics * Linda Gau + Ying Luan * Brian Munneke * William Ju Janssen R&D *

Pharmacyclics — Technical Presentation (June 2013) on 6ix